0000899243-21-002119.txt : 20210114 0000899243-21-002119.hdr.sgml : 20210114 20210114205725 ACCESSION NUMBER: 0000899243-21-002119 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210112 FILED AS OF DATE: 20210114 DATE AS OF CHANGE: 20210114 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hatzis-Schoch Brent CENTRAL INDEX KEY: 0001637054 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39200 FILM NUMBER: 21530330 MAIL ADDRESS: STREET 1: C/O RADIUS HEALTH, INC. STREET 2: 950 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Black Diamond Therapeutics, Inc. CENTRAL INDEX KEY: 0001701541 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE MAIN STREET, 10TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-417-5868 MAIL ADDRESS: STREET 1: ONE MAIN STREET, 10TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Aset Therapeutics, Inc. DATE OF NAME CHANGE: 20170321 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-01-12 0 0001701541 Black Diamond Therapeutics, Inc. BDTX 0001637054 Hatzis-Schoch Brent C/O BLACK DIAMOND THERAPEUTICS, INC. ONE MAIN STREET, 10TH FLOOR CAMBRIDGE MA 02142 0 1 0 0 See Remarks Common Stock 2021-01-12 4 M 0 4078 3.20 A 12478 D Common Stock 2021-01-12 4 M 0 7500 10.86 A 19978 D Common Stock 2021-01-12 4 S 0 2048 29.9236 D 17930 D Common Stock 2021-01-12 4 S 0 1669 30.5043 D 16261 D Common Stock 2021-01-12 4 S 0 147 31.9077 D 16114 D Common Stock 2021-01-12 4 S 0 103 32.4974 D 16011 D Common Stock 2021-01-12 4 S 0 100 34.125 D 15911 D Common Stock 2021-01-12 4 S 0 7511 35.9999 D 8400 D Stock Option (Right to Buy) 3.20 2021-01-12 4 M 0 4078 0.00 D 2029-06-11 Common Stock 4078 176786 D Stock Option (Right to Buy) 10.86 2021-01-12 4 M 0 7500 0.00 D 2029-12-04 Common Stock 7500 71251 D Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.315 to $30.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.335 to $30.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.46 to $32.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.495 to $32.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.95 to $36.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. 25% of the shares subject to this option vested and became exercisable on May 22, 2020, with the remainder vesting in 36 equal monthly installments thereafter. 25% of the shares subject to this option vested and became exercisable on December 5, 2020, with the remainder vesting in 36 equal monthly installments thereafter. Chief Operating Officer and General Counsel /s/ Brent Hatzis-Schoch 2021-01-14